Browsing Tag

AQST109

Aquestive Therapeutics Reports Positive Initial Topline Data from Part 3 of EPIPHAST…

Eli Pacheco Jun 16, 2022 0

AQST-109 is the first and only orally delivered epinephrine product candidate in clinical developmentFastest median time to maximum concentration (Tmax) in studies to date at 12 minutes…

Health

Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-109 for Emergency…

Eli Pacheco Mar 17, 2022 0

WARREN, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current…

Health

Aquestive Therapeutics Reports Positive Topline Data from Part 1 of EPIPHAST Trial…

Eli Pacheco Feb 26, 2022 0

First and only orally delivered epinephrine product candidate AQST-109 continues to show rapid absorption with a median time to peak concentration (Tmax) of 13.5 minutes AQST-109 was safe…

Health

Aquestive Therapeutics Announces FDA Clearance of Investigational New Drug…

Eli Pacheco Feb 25, 2022 0

WARREN, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current…

Health

Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic…

Eli Pacheco Oct 26, 2021 0

First and only orally delivered epinephrine product candidate AQST-109 demonstrates clinical results comparable to autoinjectors (such as EpiPen® and Auvi-Q®) for the emergency treatment of…